Xiang Gui Yang | Clinical Microbiology | Best Researcher Award

The First Affiliated hospital of Chengdu Medical College | China

AUTHOR PROFILE

EARLY ACADEMIC PURSUITS

Yang Xianggui embarked on his academic journey at Harbin Medical University, where he earned a Bachelor's degree in Medical Laboratory Science. He further advanced his education at Chongqing Medical University, obtaining a Master's degree in Clinical Laboratory Diagnostics from the School of Laboratory Medicine.

PROFESSIONAL ENDEAVORS

Since July 2015, Yang Xianggui has been serving as the Deputy Chief Laboratory Physician at the First Affiliated Hospital of Chengdu Medical College. His primary focus is on research into bacterial resistance mechanisms and virulence, positioning him as a significant contributor to this critical field of medical research.

CONTRIBUTIONS AND RESEARCH FOCUS ON CLINICAL MICROBIOLOGY

Dr. Yang's research endeavors have been substantial and varied, including:

CRISPR/Cas9 Technology: Utilizing CRISPR/Cas9 to knock out the ftsZ gene in bacteria to study the molecular regulatory mechanism of the key enzyme MpI in the peptidoglycan cycle.
Gene Knockout Studies: Investigating the regulatory mechanism of acute-chronic infection transformation based on the nagZ gene knockout in Enterobacter cloacae.
MicroRNA Research: Exploring the application of miR-135 in detecting early-onset chronic kidney disease.
Enzyme and Protein Studies: Examining the correlation between Klebsiella pneumoniae KPC-2 enzyme and OmpK36, and studying the molecular regulatory mechanism of AmpC beta-lactamase, a key enzyme in the peptidoglycan cycle.

IMPACT AND INFLUENCE

Dr. Yang has been the principal investigator on several high-impact research projects funded by notable organizations:

National Natural Science Youth Foundation Project: CRISPR/Cas9 technology study on ftsZ gene knockout.
Sichuan Provincial Natural Science Foundation General Project: Regulatory mechanism study on acute-chronic infection transformation.
Sichuan Provincial Department of Education Fund: Research on miR-135's application in early-onset chronic kidney disease detection.
Chengdu Medical University Fund: Correlation study between Klebsiella pneumoniae KPC-2 enzyme and OmpK36.
Special Fund of the First Affiliated Hospital of Chengdu Medical College: Study on the molecular regulatory mechanism of AmpC beta-lactamase.

ACADEMIC CITES

Dr. Yang has published nine SCI papers as the first author or corresponding author, showcasing his contributions to the scientific community. His work is recognized and cited by peers, reflecting his influence and expertise in bacterial resistance mechanisms and clinical laboratory diagnostics.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Yang's ongoing research projects and completed studies contribute significantly to the understanding of bacterial resistance and virulence. His legacy is built on his dedication to advancing laboratory medicine through innovative research and collaborative efforts. Future contributions are anticipated in the areas of infection control, molecular diagnostics, and bacterial resistance management, further enhancing his impact on medical science and patient care.

IMPORTANT TOPICS

BACTERIAL RESISTANCE MECHANISMS: Exploring how bacteria develop resistance to antibiotics and identifying potential targets for new treatments.
VIRULENCE FACTORS: Investigating the components that make bacteria pathogenic and how they can be neutralized.
MOLECULAR REGULATORY MECHANISMS: Understanding the intricate molecular pathways that govern bacterial behavior and resistance.
GENE KNOCKOUT TECHNOLOGIES: Utilizing advanced gene-editing tools like CRISPR/Cas9 to study bacterial genetics and physiology.
CLINICAL APPLICATIONS: Translating research findings into practical applications in clinical diagnostics and treatment strategies.

NOTABLE PUBLICATIONS

PCT, IL-6, and IL-10 facilitate early diagnosis and pathogen classifications in bloodstream infection 2023(4)

Resistance of Klebsiella pneumoniae to Phage hvKpP3 Due to High-Molecular Weight Lipopolysaccharide Synthesis Failure 2023(3)

Application of Single-Cell Genomics in Cardiovascular Research 2023(2)

Cefazolin and imipenem enhance AmpC expression and resistance in NagZ-dependent manner in Enterobacter cloacae complex 2023(3)

Candida tropicalis distribution and drug resistance is correlated with ERG11 and UPC2 expression 2021(33)

EARLY ACADEMIC PURSUITS

Bin Zhang's journey into the world of medical research began with a solid foundation in biomedical sciences. His early academic pursuits were marked by a dedication to understanding complex biological systems and a passion for contributing to the field of oncology. This academic dedication led him to become a young expert recognized under the prestigious Taishan Mount Scholars program in China.

PROFESSIONAL ENDEAVORS

In 2018, Bin Zhang was appointed as a researcher at the Affiliated Hospital of Jining Medical University. Here, he established the tumor metabolism research group, assuming the role of Principal Investigator. Under his leadership, the group has grown to focus on four key research directions: the regulatory mechanisms of tumor stem cells, the specificity of tumor biomacromolecules and energy metabolism, the regulation of energy metabolism by oncogenic gene mutations, and the screening of potential drugs targeting tumor metabolism.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE MUTATION

Bin Zhang's research has significantly advanced the understanding of tumor metabolism. His work has been published in esteemed journals such as Cell Reports Medicine, Biomaterials, Oncogene, Journal of Experimental & Clinical Cancer Research, and Stem Cells. These publications highlight his team's investigations into the intricate mechanisms of tumor biology and potential therapeutic targets. The research group delves into how tumor stem cells are regulated, how tumor biomacromolecules function, and how mutations in oncogenes affect energy metabolism, all of which are crucial for developing new cancer treatments.

IMPACT AND INFLUENCE

The impact of Bin Zhang's research is reflected in the high citation rate of his publications, with over 5000 citations to date and an H-Index of 34. His work has not only contributed valuable knowledge to the scientific community but has also influenced ongoing research and development in tumor metabolism. Furthermore, Bin Zhang has successfully secured ten patents, two of which have been transferred, demonstrating the practical applications and commercial potential of his research findings.

ACADEMIC CITES

Bin Zhang is also an active member of the academic community, serving as a reviewer for several high-impact journals including Stem Cells and Development, EBioMedicine, Stem Cell Research & Therapy, Molecular Carcinogenesis, and the Journal of Clinical Laboratory Medicine. His expertise is sought after in evaluating cutting-edge research and ensuring the quality of publications in these journals.

LEGACY AND FUTURE CONTRIBUTIONS

Bin Zhang's legacy in the field of tumor metabolism is marked by his innovative research and commitment to advancing cancer treatment. Currently, he is the principal investigator of two general projects funded by the National Natural Science Foundation of China, two projects funded by Shandong Province, and two projects funded by the Postdoctoral Foundation of China. His ongoing work promises to uncover new insights and develop novel therapies, continuing to push the boundaries of cancer research